Anavex Life Sciences Corp (AVXL)

[Doc328]

Yes, the study is a phase 2b that has endpoints appropriate for a phase 3 and can be modified based on data from initial completers to determine if it will be enlarged into a phase 3, possibly dropping one treatment arm to increase enrollment in the other). The 450 screened patients will be randomized +/- 150 to placebo, mid-dose and high dose. Most likely 0/30/50 mg but 0/10/20 mg is still a possibility.